PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1944487
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1944487
The Cardiac Mapping Market size was valued at US$3,789.12 Million in 2024, expanding at a CAGR of 7.5% from 2025 to 2032.
Cardiac mapping functions as an advanced electrophysiological method which enables doctors to track and study heart electrical patterns for the purpose of identifying and treating heart rhythm disorders. The process requires the insertion of catheter-based electrodes into the heart which they use to collect electrical data that produces detailed maps of abnormal electrical impulse propagation in the heart. Advanced cardiac mapping systems create two-dimensional and three-dimensional electro-anatomical maps which allow doctors to find arrhythmogenic tissue and direct catheter ablation treatments while enhancing their procedural effectiveness and patient results. Cardiac mapping functions as a standard method for treating atrial fibrillation and atrial flutter and ventricular tachycardia while serving as a vital component of current minimally invasive cardiac electrophysiology procedures.
Cardiac Mapping Market- Market Dynamics
Aging population and rising CVD burden
The cardiac mapping market experiences expansion because of two primary factors which include the increasing number of elderly people and the growing prevalence of cardiovascular diseases. The structural and electrical changes that occur in the heart because of aging make older adults more vulnerable to cardiac arrhythmias which include atrial fibrillation and atrial flutter and ventricular tachycardia. The global population experiences rising cardiovascular disease risk factors through increasing rates of hypertension and diabetes and obesity and lack of physical activity which results in more people developing rhythm disorders that need complete diagnostic and treatment solutions. The need for electrophysiology procedures is increasing especially for catheter ablation procedures which use cardiac mapping systems as hospitals and cardiac care centers seek to improve their diagnostic capabilities and procedure results and patient health through advanced cardiac mapping technologies.
By Type
In 2024, the contact cardiac mapping systems segment holds the largest market share. The growth is due to increasing number of patient admissions for the treatment of heart abnormalities, which creates growing need for advanced cardiac mapping systems throughout the world. The segment will continue to expand because major companies now work to obtain approval for their cardiac mapping systems.
Cardiac Mapping Market- Geographical Insights
North America leads the industry. The United States and Canada exhibit market control because of their high occurrence of cardiac rhythm disorders and their established heart treatment facilities and their complete use of modern mapping systems and their presence of major medical equipment manufacturers. North America will keep its market leadership position through future years because of rising treatment numbers and continuous technological advancements and ongoing funding for electrophysiology development which will drive substantial growth in the cardiac mapping market throughout both regional and global markets.
The competitive landscape of the cardiac mapping market is led by a handful of large medtech firms that dominate through broad portfolios, global distribution, and heavy R&D investment-most notably Biosense Webster (Johnson & Johnson), Abbott, Boston Scientific, and Medtronic-while other established names (Philips, Siemens/GE partners, BIOTRONIK) and regional players (MicroPort, Lepu) fill out the field. The leading companies in the industry compete against each other by launching new mapping platforms and catheters which include 3D electro-anatomical systems and high-density/real-time mapping and integrated imaging and AI functionalities because these products create higher costs for customers who want to switch and they decrease the time products remain competitive in the market. A wave of smaller, fast-moving companies and startups (Acutus, Kardium, Biosig, Ablacon and others) develop niche advantages through their innovative sensor designs and signal-processing algorithms and affordable systems which drive established companies to develop new products and form partnerships and pursue targeted mergers and acquisitions.
In February 2025, Boston Scientific Corporation announced it has received CE mark for the navigation-enabled FARAWAVE(TM) NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) and for the new FARAVIEW(TM) Software. Both technologies will integrate and expand mapping option capabilities for cardiac ablation procedures using the FARAPULSE(TM) Pulsed Field Ablation (PFA) System, the most clinically proven PFA system for the treatment of AF, which has already benefited 200,000 patients globally. These technologies are compatible exclusively with the company's existing cardiac mapping technology and the company's latest offering, the OPAL HDx(TM) Mapping System.
In December 2025, Abbott announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt(TM) PFA System to treat patients battling atrial fibrillation (AFib). Abbott will soon begin commercial PFA cases in the United States and will continue its expansion of sites in the European Union following Volt CE Mark approval earlier this year.